Digitisation | September 13, 2023
AI to transform all processes in drug development by 2026, predicts CPHI Report
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging
Advancing to IND-enabling studies with multiple drug candidates
The facility is among 12 centres established worldwide, and the first in Asia
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
The goal for the project is the identification and optimization of anti-viral compounds.
At the latest Indian Pharma Post E-Conference, leading experts identified faster regulatory approvals, infrastructure, digital innovation, investigator training, and public trust as critical pillars
34% of pharma firms have already deployed function-specific AI, with drug discovery, clinical trials, and medical writing emerging as key high-impact use cases
Subscribe To Our Newsletter & Stay Updated
